Research Paper Volume 15, Issue 16 pp 7997—8012
HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma
Figure 3. Validation of the prognostic value of HYDIN status. The Kaplan–Meier curve of overall survival in the anti-CTLA4 treated cohort (A). Histogram depicting proportions of ORR (B) and DCB (C) in HYDIN-MUT and HYDIN-WT patients in the anti-CTLA4 treated cohort. Kaplan–Meier curves of overall survival in the total ICIs treatment cohort (D). Histogram depicting proportions of ORR (E) and DCB (F) in HYDIN-MUT and HYDIN-WT patients in the total ICIs treatment cohort. DCB, durable clinical benefit; ORR, objective response rate; HYDIN-MUT, HYDIN mutations; HYDIN-WT, HYDIN wild-type; anti-CTLA4, anti-cytotoxic T-lymphocyte associated protein 4.